PMID: 26367736 [26] Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al
JavaScript is disabledTo browse the Basharacare store,enable JavaScript in your browser.
Other groups have reported increased efficacy with 5FU and metformin in models of acquired resistance 53,54,55,56 , in spheroid culture 53 or xenograft/PDX models 57,58,59 , but the potential of combined 5FUCI inhibitor co-treatment in a chemo-naive, immune-competent setting requires further investigation
The FDA warns that both CJC-1295 and ipamorelin carry risks of immunogenicity (triggering immune responses) and cardiovascular effects, including "increased heart rate and systemic vasodilatory reaction." One clinical trial of CJC-1295 was discontinued following a participants death, though the attending physician believed the event was "unrelated to treatment." Neither CJC-1295 nor ipamorelin is FDA-approved